U2AF2 and metastatic melanoma: Additionally, metastatic melanoma patients (stage IIIB–C) with high ILF2‐U2AF2 mRNA levels showed significantly shorter OS compared to patients with low ILF2‐U2AF2 mRNA levels (p = .024, Figure 3G).